Under the weather: an epidemic thunderstorm asthma event in Leicester, June 2023
- PMID: 40250847
- PMCID: PMC12007050
- DOI: 10.1136/bmjresp-2024-002588
Under the weather: an epidemic thunderstorm asthma event in Leicester, June 2023
Abstract
In the context of climate change and increasing global populations, thunderstorm asthma may become a greater threat at both individual and population levels. The unpredictable nature of epidemic thunderstorm asthma events makes them challenging to study; however, they can have devastating consequences. Novel approaches are required to characterise the mechanisms driving these events to allow researchers and other stakeholders to understand who is at risk and when. This will support the development of interventions that protect patients and healthcare services. In this commentary, we provide an overview of thunderstorm asthma and briefly describe an epidemic affecting Leicester, UK in June 2023. Our analysis highlights Cladosporium spores as a key player in mediating UK thunderstorm asthma. Low levels of background treatment in adults and an increase in emergency assessments but not hospitalisations in children suggest that epidemics could be prevented by improving awareness and ensuring access to standard inhaled therapies. Finally, we consider future risk and suggest research priorities with an ultimate goal of minimising the adverse impact related to thunderstorm asthma going forward.
Keywords: Allergic lung disease; Asthma; Clinical Epidemiology; Paediatric asthma.
© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
Competing interests: FS, JS, HL, RHG, GW and LC have no relevant conflicts of interest. SD has received consultancy fees from AstraZeneca. DR has received grants from the National Institute for Health Research (NIHR). EAG is the secretary of the European Respiratory Society Paediatric Asthma and Allergy Group and has received grants from Propeller Health, Adherium and AstraZeneca, honoraria from Circassia and honoraria and travel support from Sanofi. AH has received funding with the NIHR Leicester Biomedical Research Centre and the NIHR Health Protection Research Unit in Environmental Exposures and Health development award at the University of Leicester. CB has received grants and consultancy fees from 4D Pharma, Areteia, AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Mologic, Novartis, Regeneron Pharmaceuticals, Roche and Sanofi.
Figures




References
-
- Cisse G, McLeman R, Adams H, et al. Climate change 2022: impacts, adaptation and vulnerability. Cambridge University Press; 2022. Health, wellbeing and the changing structure of communities; pp. 1041–170.
-
- World Health Organisation Climate change 2024. [26-Mar-2024]. https://www.who.int/health-topics/climate-change#tab=tab_1 Available. Accessed.
-
- Pawankar R, Canonica G, Holgate S, et al. White book on allergy: update 2013. World Allergy Organisation; 2013.
-
- European Academy of Allergy and Clinical Immunology Global Atlas of Allergy. 2014 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical